| Primary |
| Product Used For Unknown Indication |
15.6% |
| Stem Cell Transplant |
11.5% |
| Histiocytosis Haematophagic |
10.4% |
| Aplastic Anaemia |
7.3% |
| Renal Transplant |
6.3% |
| Prophylaxis Against Graft Versus Host Disease |
5.2% |
| Prophylaxis Against Transplant Rejection |
5.2% |
| Corneal Transplant |
4.2% |
| Dyspepsia |
4.2% |
| Liver Transplant |
4.2% |
| Lung Transplant |
4.2% |
| Infection Prophylaxis |
3.1% |
| Juvenile Arthritis |
3.1% |
| Nephrotic Syndrome |
3.1% |
| Acute Hepatic Failure |
2.1% |
| Castleman's Disease |
2.1% |
| Chronic Hepatitis C |
2.1% |
| Cord Blood Transplant Therapy |
2.1% |
| Myeloproliferative Disorder |
2.1% |
| Nephritis |
2.1% |
|
| Immunosuppressant Drug Level Increased |
7.4% |
| Ocular Hyperaemia |
7.4% |
| Renal Failure |
7.4% |
| Renal Impairment |
7.4% |
| Rhabdomyolysis |
7.4% |
| Vision Blurred |
7.4% |
| Visual Acuity Reduced |
7.4% |
| Aortic Aneurysm |
3.7% |
| Bronchitis |
3.7% |
| Cerebral Ischaemia |
3.7% |
| Death |
3.7% |
| Drug Resistance |
3.7% |
| Graft Versus Host Disease |
3.7% |
| Graft Versus Host Disease In Intestine |
3.7% |
| Intentional Drug Misuse |
3.7% |
| Interstitial Lung Disease |
3.7% |
| Leukoencephalopathy |
3.7% |
| Paraesthesia |
3.7% |
| Pneumonia |
3.7% |
| Pneumonitis |
3.7% |
|
| Secondary |
| Cord Blood Transplant Therapy |
19.8% |
| Prophylaxis |
14.5% |
| Cytomegalovirus Infection |
10.8% |
| Insomnia |
5.0% |
| Bone Marrow Transplant |
4.9% |
| Product Used For Unknown Indication |
3.9% |
| Stem Cell Transplant |
3.8% |
| Immunosuppression |
3.2% |
| Cholestasis |
3.1% |
| Hypothyroidism |
3.1% |
| Juvenile Idiopathic Arthritis |
3.1% |
| Aspergillus Infection |
3.1% |
| Depression |
3.1% |
| Oedema Peripheral |
3.1% |
| Gastroduodenal Ulcer |
2.9% |
| Idiopathic Pulmonary Fibrosis |
2.9% |
| Chemotherapy |
2.6% |
| Hypertension |
2.6% |
| Renal Transplant |
2.5% |
| Anxiety |
1.8% |
|
| Thrombotic Microangiopathy |
40.7% |
| Respiratory Failure |
8.8% |
| Sepsis |
7.7% |
| Renal Impairment |
4.4% |
| Thrombotic Thrombocytopenic Purpura |
4.4% |
| Immunosuppressant Drug Level Increased |
3.3% |
| Insomnia |
3.3% |
| Renal Failure |
3.3% |
| Drug Clearance Decreased |
2.2% |
| Femoral Neck Fracture |
2.2% |
| Pancytopenia |
2.2% |
| Pneumonia Staphylococcal |
2.2% |
| Pyrexia |
2.2% |
| Thermal Burn |
2.2% |
| Urticaria |
2.2% |
| Venoocclusive Liver Disease |
2.2% |
| Visual Acuity Reduced |
2.2% |
| Vomiting |
2.2% |
| Bacterial Infection |
1.1% |
| Coronary Artery Stenosis |
1.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.7% |
| Prophylaxis |
16.4% |
| Juvenile Idiopathic Arthritis |
11.7% |
| Renal Transplant |
2.9% |
| Infection Prophylaxis |
2.3% |
| Bacterial Infection |
2.2% |
| Nausea |
2.0% |
| Vomiting |
1.8% |
| Behcet's Syndrome |
1.6% |
| Immunosuppression |
1.6% |
| Acute Graft Versus Host Disease |
1.5% |
| Immunosuppressant Drug Therapy |
1.5% |
| Prophylaxis Against Graft Versus Host Disease |
1.5% |
| Acute Lymphocytic Leukaemia |
1.3% |
| Gout |
1.3% |
| Infection |
1.3% |
| Acute Myeloid Leukaemia |
1.2% |
| Bone Marrow Conditioning Regimen |
1.2% |
| Cardiovascular Event Prophylaxis |
1.0% |
| Diuretic Therapy |
1.0% |
|
| Jaundice |
19.1% |
| Toxic Epidermal Necrolysis |
17.0% |
| White Blood Cell Count Decreased |
8.5% |
| Fluoride Increased |
4.3% |
| Myoclonus |
4.3% |
| Nephrogenic Systemic Fibrosis |
4.3% |
| Neutropenia |
4.3% |
| Pneumonia Cytomegaloviral |
4.3% |
| Pyrexia |
4.3% |
| Sepsis |
4.3% |
| Upper Respiratory Tract Inflammation |
4.3% |
| Wrist Fracture |
4.3% |
| Adenocarcinoma Of Colon |
2.1% |
| C-reactive Protein Increased |
2.1% |
| Cardiac Failure Acute |
2.1% |
| Drug-induced Liver Injury |
2.1% |
| Epilepsy |
2.1% |
| Erysipelas |
2.1% |
| Gastrointestinal Haemorrhage |
2.1% |
| Gastrointestinal Inflammation |
2.1% |
|
| Interacting |
| Heart Transplant |
27.8% |
| Heparin-induced Thrombocytopenia |
27.8% |
| Nephritis |
22.2% |
| Dyslipidaemia |
11.1% |
| Immunosuppressant Drug Therapy |
11.1% |
|
| Drug Level Decreased |
55.6% |
| Immunosuppressant Drug Level Increased |
22.2% |
| Renal Failure Acute |
22.2% |
|
